Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

News & events

Home > News & events

Here you can find news and features relating to the NOVELTY study as we embark on this journey of discovery.

Extra news for investigators and AstraZeneca Medical employees

Events

Read More

News

6th July, 2021

Validation of the CAAT in NOVELTY ePoster Presented at ATS 2021

Read More

30th March, 2021

NOVELTY baseline characteristics manuscript published

Read More

26th February, 2021

Respiratory Symptoms Questionnaire manuscript published

Read More

26th February, 2021

NOVELTY at ISPOR Europe 2020

The humanistic burden of mild asthma – ePoster presented at the virtual ISPOR Europe Conference 2020.
Read More

21st December, 2020

NOVELTY at ERS 2020

We are pleased to announce that six NOVELTY abstracts were presented as ePosters at the virtual European Respiratory Society (ERS) Congress 2020 on 7–9 September – you can read summaries of these ePosters here. The related abstracts have now been published in a supplement to the online version of the European Respiratory Journal. The presentations cover the following topics: Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD Factors associated with physician assessment of severity of asthma or COPD Disease burden in...
Read More

17th November, 2020

Observational studies review published

We are pleased to announce that ‘Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design’ has been published in ERJ Open Research.1 This article, authored by members of the NOVELTY Scientific Community, examines the value of observational studies, alongside randomised controlled trials (RCTs) in the field of obstructive lung disease. Although RCTs are very important for evaluating treatment efficacy in patients with obstructive lung disease, this review highlights that observational studies are also a highly valuable part of the research effort and could be significant in moving towards a more personalised approach...
Read More

14th July, 2020

NOVELTY at ATS 2020

The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study ...
Read More

3rd June, 2020

The COVID-19 pandemic and NOVELTY

The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study. The NOVELTY study provides a unique opportunity to better understand the risk and outcomes of COVID-19 infection in patients with asthma and/or COPD.
Read More

18th March, 2020

An update on NOVELTY governance: the NOVELTY Scientific Community

The NOVELTY Scientific Community was established at the annual face-to-face meeting on 22 January 2020. This new structure represents an evolution in the NOVELTY scientific strategy, setting and delivery, bringing together the separate bodies of the Scientific Committee, the National Principal Investigators and the AstraZeneca science and evidence leads.
Read More

10th December, 2019

Severe obstructive lung disease review article published

We are pleased to announce that a review article entitled ‘Defining severe obstructive lung disease in the biologic era: an endotype-based approach’ has been published in the European Respiratory Journal.
Read More

7th April, 2016

A message from the NOVELTY Scientific Committee

We are very pleased to announce the launch of the NOVELTY study, and are enthusiastic to be working with physicians and study centres around the world to increase our knowledge of obstructive lung disease on a global, local and individual patient level.
Read More
19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
84% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study